Serum ocrelizumab concentrations in patients with multiple sclerosis: A cross-sectional study from routine healthcare

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F25%3AE0111815" target="_blank" >RIV/00843989:_____/25:E0111815 - isvavai.cz</a>

Alternative codes found

RIV/61988987:17110/25:A2603DKZ

Result on the web

<a href="https://doi.org/10.1016/j.msard.2025.106591" target="_blank" >https://doi.org/10.1016/j.msard.2025.106591</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.msard.2025.106591" target="_blank" >10.1016/j.msard.2025.106591</a>

Result language

angličtina

Original language name

Serum ocrelizumab concentrations in patients with multiple sclerosis: A cross-sectional study from routine healthcare

Original language description

Background: Ocrelizumab is a humanised monoclonal antibody used to treat multiple sclerosis. In this cross-sectional study, the serum concentrations of ocrelizumab obtained during routine healthcare of patients with multiple sclerosis were measured using ultra-performance liquid chromatography with tandem mass spectrometry. Methods: The study group included 180 patients who received either an initial dose of 300 mg or at least one complete dose of 600 mg intravenously administered ocrelizumab. Patients were stratified into two subgroups according to the time of blood collection (? 28 weeks and > 28 weeks post-dose). Blood counts and immunoglobulin A, G, and M concentrations were also recorded. Results: Serum ocrelizumab concentrations ranged between 20.5-62.4 mg/L in patients with the initial dose of 300 mg and between 0.3-21.8 mg/L in patients with at least one complete 600 mg dose. A significant inverse correlation was observed between serum ocrelizumab concentration and body weight, height, body surface area, and body mass index. Significantly lower ocrelizumab concentrations were observed in patients with a collection time > 28 weeks compared to ? 28 weeks. An inverse correlation was observed between ocrelizumab concentrations and haematological parameters (leukocyte count, absolute lymphocyte, neutrophil and eosinophil counts, and differential eosinophil count), and immunoglobulin A and G concentrations. Conclusion: Wide interindividual variability in serum concentrations was observed in both the group of patients who received an initial intravenous dose of 300 mg ocrelizumab and in patients who received at least one complete dose of 600 mg. This variability in ocrelizumab pharmacokinetics was also evident when samples were collected at similar time after dosing and may lead to both toxicity and the risk of suboptimal drug concentrations.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30104 - Pharmacology and pharmacy

Project

—

Continuities

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year

2025

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Multiple sclerosis and related disorders

ISSN

2211-0348

e-ISSN

2211-0356

Volume of the periodical

101

Issue of the periodical within the volume

article 106591

Country of publishing house

NL - THE KINGDOM OF THE NETHERLANDS

Number of pages

11

Pages from-to

1-11

UT code for WoS article

001568427200002

EID of the result in the Scopus database

2-s2.0-105008778972